Technology NetworksStem Cells and Regenerative Medicine Global SummitTechnology NetworksThe discovery of stem cell has revolutionized the medical world. Ever since the pioneering work of Canadian scientists, Dr. James Till and Dr. Ernest McCulloch, ste… Continue reading
Medscape |
Immunotherapy Promising in Parkinson’s Disease
Medscape VANCOUVER — Immunotherapy using a novel monoclonal antibody appears to be a promising new approach to treating Parkinson’s disease (PD). A phase 1b study of a humanized IgG1 monoclonal antibody directed against α-synuclein (PRX002, … |
Medscape |
Immunotherapy Promising in Parkinson’s Disease
Medscape VANCOUVER — Immunotherapy using a novel monoclonal antibody appears to be a promising new approach to treating Parkinson’s disease (PD). A phase 1b study of a humanized IgG1 monoclonal antibody directed against α-synuclein (PRX002, … |
|
TCR(2) Therapeutics Presents Positive Solid Tumor Data for its Novel TRuC™ Engineered T Cell Therapies at the …
PR Newswire (press release) CAMBRIDGE, Mass., June 13, 2017 /PRNewswire/ — TCR2 Therapeutics Inc. announced data today on two of its TRuC™ programs that showed superior persistence and anti-tumor activity of the company’s TRuC™-T cells compared to CAR–T cells in … |
PR Newswire (press release) |
Stem Cell Therapy Becomes Law in Texas
PR Newswire (press release) LA JOLLA, Calif., June 13, 2017 /PRNewswire/ — House Bill (HB 810) on stem cell therapy has passed in the Texas state legislature and become law. Patients in Texas will now have access to this “Right to Try” innovative form of therapy for those … |
|
Threshold Pharmaceuticals Announces First Patient Dosed in Immunotherapy Clinical Trial of Evofosfamide and …
Nasdaq “We believe that adding evofosfamide to certain immunotherapies has the potential to render some of the most therapeutically resistant cancers more sensitive to the immunotherapy and we are excited to have dosed the first patient in this study,” said … |
|
Threshold Pharmaceuticals Announces First Patient Dosed in Immunotherapy Clinical Trial of Evofosfamide and …
GlobeNewswire (press release) “We believe that adding evofosfamide to certain immunotherapies has the potential to render some of the most therapeutically resistant cancers more sensitive to the immunotherapy and we are excited to have dosed the first patient in this study,” said … |